Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2007-08-28
2007-08-28
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C514S114000, C558S157000
Reexamination Certificate
active
11134218
ABSTRACT:
Sulfonylethyl and thioethyl phosphorodiamidates, their preparation and intermediates in their preparation, formulations containing them, and their pharmaceutical use. The compounds are useful for treating cancer, alone and in combination with other anticancer therapies.
REFERENCES:
patent: 5545621 (1996-08-01), Kauvar et al.
patent: 5556942 (1996-09-01), Kauvar et al.
patent: 6506739 (2003-01-01), Herr et al.
patent: WO95/09865 (1995-04-01), None
patent: WO95/09866 (1995-04-01), None
patent: WO 01/83496 (2001-11-01), None
patent: 2005/017880 (2005-11-01), None
patent: WO 2005/118601 (2005-12-01), None
Brain tumor, Wikipedia, the free encyclopedia article, p. 1-5 (on-line publication, Aug. 30, 2006).
Chul-Hoon Kwon et al., “Chemically Stable, Lipophilic Prodrugs of Phosphoramide Mustard as Potential Anticancer Agents”J. Med. Chem.(1991) 34:588-592.
Yuan-Wan Sun et al., “Utilization of sufonylethyl groups in the design of nucleotide prodrugs”Proc. Am. Assn. Cancer Res.(2002) 43:208 (Abstract No. 1041).
Monish Jain et al. “1,2-Benzisoxazole Phosphorodiamidates as Novel Anticancer Prodrugs Requiring Bioreductive Activation”J. Med. Chem.(2002) 46:5428-5436.
Monish Jain et al. “Sulfonyl-Containing Aldophosphamide Analogues as Novel Anticancer Prodrugs Targeted against cyclophosphamide-Resistant Tumor Cell Lines”J. Med. Chem.(2004) 3843-3852 Published on the web Jun. 17, 2004 and in print Jul. 15, 2004.
Jain M et al:“Sulfonyl-containing aldophosphamide analogues as novel anticancer prodrugs targeted against cyclophosphamide-resistant tumor cell lines.” Journal of Medicinal Chemistry, vol. 47,No. 15, Jul. 15, 2004, pp. 3843-3852, XP002354374 ISSN: 0022-2623 Chart 2 on p. 3844 Schemes 3, 4 & 5 on p. 3845, steps (c).
Rosario L A et al:“Cellular response to a glutathione 5-transferase P1-1 activated prodrug.” Molecular Pharmacology, vol. 58,No. 1, Jul. 2000, pp. 167-174, XP002354375 ISSN: 0026-895X cited in the application figure 1.
Satyam A et al:“Design, Synthesis, and Evaluation of Latent Alkylating Agents activated by Glutathione S-Transferase” Journal of Medicinal Chemistry, vol. 39,1996, pp. 1736-1747, XP002351413 ISSN: 0022-2623 Compounds 2-5.
Ciaccio P J et al: “Modulation of detoxification gene expression in human colon HT29 cells byglutathione-S-transferase inhibitors”Molecular Pharmacology, vol. 48,No. 4, Oct. 1, 1995, pp. 639-647, XP000601686 ISSN: 0026-895X TER 286.
Lyttle M H et al: “Glutathione-S-transferase activates novel Alkylating Agents” Journal of Medicinal Chemistry, vol. 37,1994, pp. 1501-1507, XPOO2351412 ISSN: 0022-2623 Compounds 2 & 3.
Robinson Louise
Schow Steven R.
Shi Songyuan
McKane Joseph K.
Telik, Inc.
LandOfFree
Sulfonylethyl phosphorodiamidates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfonylethyl phosphorodiamidates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfonylethyl phosphorodiamidates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3873763